Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections | Zendy

Laura Morata | Zendy; J. Cobo | Zendy; Marta Fernández-Sampedro | Zendy; Pablo GuisadoVasco | Zendy; Eric Ruano | Zendy; Jaime Lora-Tamayo | Zendy; M. Sánchez Somolinos | Zendy; Patricia GonzálezRuano | Zendy; Alicia Rico | Zendy; Ana Arnáiz | Zendy; Miriam Estébanez | Zendy; Jiménez-Mejías Me | Zendy; Ana B. Serrano | Zendy; Elena Múñez | Zendy; Dolors Rodríguez-Pardo | Zendy; Roger Argelich | Zendy; A Arroyo | Zendy; José Pablo Martínez Barbero | Zendy; Fátima Cuadra | Zendy; Alfonso del Arco | Zendy; María Dolores del Toro | Zendy; Laura Guío Carrión | Zendy; D. Jimenez-Beatty | Zendy; Noemi Lois | Zendy; Oriol MartínSolé | Zendy; Rubén Álvarez | Zendy; Francisco Javier Martı́nez-Marcos | Zendy; L. Porras | Zendy; M.F. Ramírez | Zendy; Javier García | Zendy; Álex Soriano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections

Author(s) -

Laura Morata,

J. Cobo,

Marta Fernández-Sampedro,

Pablo GuisadoVasco,

Eric Ruano,

Jaime Lora-Tamayo,

M. Sánchez Somolinos,

Patricia GonzálezRuano,

Alicia Rico,

Ana Arnáiz,

Miriam Estébanez,

Jiménez-Mejías Me,

Ana B. Serrano,

Elena Múñez,

Dolors Rodríguez-Pardo,

Roger Argelich,

A Arroyo,

José Pablo Martínez Barbero,

Fátima Cuadra,

Alfonso del Arco,

María Dolores del Toro,

Laura Guío Carrión,

D. Jimenez-Beatty,

Noemi Lois,

Oriol MartínSolé,

Rubén Álvarez,

Francisco Javier Martı́nez-Marcos,

L. Porras,

M.F. Ramírez,

Javier García,

Álex Soriano

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02280-18

Subject(s) - dalbavancin , joint infections , medicine , intensive care medicine , surgery , biology , staphylococcus aureus , vancomycin , bacteria , genetics , periprosthetic , arthroplasty

Dalbavancin is a lipoglycopeptide with potent activity against Gram-positive microorganisms, a long half-life, a favorable safety profile, and a high concentration in bone, which makes it an interesting alternative for treatment of osteoarticular infections. We performed a multicentric retrospective study of all patients with an osteoarticular infection (septic arthritis, spondylodiscitis, osteomyelitis, or orthopedic implant-related infection) treated with at least one dose of dalbavancin between 2016 and 2017 in 30 institutions in Spain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research